Sphenopalatine ganglion stimulation: a comprehensive evaluation across diseases in randomized controlled trials

Lingli Qin, Dian Chen, Xian Li, Yue Gao, Wanying Xia, Hanxi Dai, Linjie Qiu, Jinsheng Yang, Lu ZhangFrontiers in Neurology 2024 · DOI

Abstract

PROSPERO, identifier CRD42021252073, https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=312429.

Introduction

The Sphenopalatine Ganglion (SPG) is a major extracranial parasympathetic relay station located deep within the facial structure. As a modulator of sensory and autonomic signals to the nasal mucosa, lacrimal glands, and cerebral blood vessels, it has long been a therapeutic target for various "head-and-face" disorders. However, clinical evidence has historically been fragmented across different specialties and languages. This systematic review and network meta-analysis (NMA) aims to provide a consolidated evaluation of SPG stimulation (SPGs) across all major clinical applications to determine where the evidence is strongest.

Methodology

The authors conducted a systematic review of 36 randomized controlled trials (RCTs) published up to May 2022. To ensure a global perspective, the team searched both Western (PubMed, Embase) and Chinese (CNKI, Wanfang, VIP, CBM) databases.

Figure 1: Flowchart of the study selection process, detailing the screening of 916 records to arrive at the final 36 included RCTs.

The study utilized Network Meta-Analysis (NMA) to compare multiple treatments—such as SPGs, Western medicine, and conventional acupuncture—even in the absence of direct head-to-head trials. Interventions were ranked using Surface Under the Cumulative Ranking (SUCRA) curves, and study quality was assessed via the Cochrane Risk of Bias tool.

Key Findings and Clinical Insights

The analysis included 36 publications, categorized as high (10), medium (23), or low (3) quality. The primary diseases studied were Allergic Rhinitis (21 trials), Ischemic Stroke (2), and Cluster Headache (2).

Allergic Rhinitis (AR)

SPGs emerged as a highly effective intervention for AR, ranking first in the SUCRA ranking for improving Quality of Life (RQLQ) scores. In terms of "Effective Rate," SPGs significantly outperformed both standard Western Medicine and Conventional Acupuncture ($P < 0.05$). This suggests that direct neuromodulation of the autonomic nervous system may be more potent for chronic sufferers than traditional pharmacological receptor blocking.

Ischemic Stroke (IS)

One of the most significant findings involved Ischemic Stroke. While SPGs showed moderate benefits for the general stroke population, it was remarkably effective for the Cerebral Cortical Infarction (CCI) subgroup. In this group, SPGs yielded a significant improvement in 3-month outcomes (modified Rankin Scale) with an Odds Ratio of 2.70 ($95\% \text{ CI}: 1.08–6.73, P = 0.03$). This indicates that SPGs may work specifically by dilating cortical arterioles to foster reperfusion.

Cluster Headache and Nasal Function

For cluster headaches, SPGs provided statistically significant relief and disappearance of symptoms within 15 minutes of stimulation. Furthermore, physiological data showed immediate and 24-hour improvements in nasal airway resistance and nasal cavity volume in both healthy volunteers and AR patients.

Discussion and Limitations

The SPG is uniquely accessible via the nasal mucosa, making it a "low-hanging fruit" for neuromodulation compared to deep-brain targets. However, the study identifies several challenges:

  • Modality Heterogeneity: The "SPGs" label covers a wide range of methods, from surgically implanted neurostimulators to acupuncture needles, with varying intensities and durations.
  • Sample Sizes: While evidence for AR and Stroke is robust, rarer conditions like pediatric secretory otitis were represented by only single trials.
  • Blinding: The physical nature of needle or electrical interventions makes double-blinding difficult, which may introduce bias in subjective reporting.

Conclusion

This comprehensive review concludes that Sphenopalatine Ganglion stimulation is a highly effective, evidence-based intervention for allergic rhinitis, ischemic stroke (specifically cortical infarctions), and cluster headaches. Future research should focus on large-scale RCTs to standardize stimulation parameters and clarify long-term therapeutic effects.

Summary updated

Abstract

PROSPERO, identifier CRD42021252073, https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=312429.
BibTeX
@inproceedings{qin2024sphenopalatine,
  author = {Lingli Qin and Dian Chen and Xian Li and Yue Gao and Wanying Xia and Hanxi Dai and Linjie Qiu and Jinsheng Yang and Lu Zhang},
  title = {{Sphenopalatine ganglion stimulation: a comprehensive evaluation across diseases in randomized controlled trials}},
  booktitle = {Frontiers in Neurology},
  year = {2024},
  doi = {10.3389/fneur.2024.1352145},
}
Figure